Safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate for hyperkalemia management in China: actualize study
Frontiers in Pharmacology · 14.05.2026 · 17
DOI: 10.3389/fphar.2026.1744687 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.05.2026. Verfasst von Nan Shen und 35 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
This real-world analysis aimed to evaluate the primary endpoint safety profile and the secondary effectiveness and treatment patterns of sodium zirconium cyclosilicate (SZC) for hyperkalemia management in China, addressing the current evidence gap on SZC use in clinical practice.
Methods
This multi-center, prospective, non-interventional cohort study enrolled patients (aged ≥18 years), including new and ongoing SZC users, from 34-sites. Treatment was categorized into correction-phase (FAS-P1) and maintenance phase (FAS-P2, new and ongoing users). The subgroup analysis was performed in patients undergoing hemodialysis (full analysis set-hemodialysis [FAS-H]). The primary objective included the safety of SZC whereas treatment patterns and effectiveness were the secondary objectives.
Results
Of the 1,000 enrolled patients, 442, 878, and 474 were included in FAS-P1, FAS-P2, and FAS-H subgroups, respectively. The most frequently used SZC dosage was 5 g once-daily in FAS-P (42.1%), and FAS-P2 (37.7%). In the FAS-P1 and FAS-P2 groups, 64% and 65.4% of patients reported AEs; 26.9% and 30.8% reported SAEs. The serum potassium (sK + ) was reduced from 5.8 to 5.0 mmol/L in FAS-P1. The mean “with-in” sK + levels over 6-month was 5.1 mmol/L in FAS-P2, of which the new-user group were slightly higher vs. ongoing group of FAS-P2 with a mean sK + of 5.2 and 5.0 mmol/L, respectively. Furthermore, SZC showed good efficacy in patients with different chronic kidney disease stage subgroups of FAS-P2.
Conclusion
In real-world clinical practice, no new safety issues of SZC were identified. SZC was effective in lowering sK + levels in the correction-phase and remained stable during the maintenance-phase.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
- Graduate School of Dalian Medical University, Dalian, China.
- Dalian Ruikaer Renal Disease Hospital, Dalian, China.
- The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Hefei First People's Hospital, Hefei, Anhui, China.
- Wenzhou Integrated Chinese and Western Medicine Hospital, Wenzhou, Zhejiang, China.
Zitieren
APA
Shen, N., Zeng, X., Xie, H., Zhang, L., Yang, J., Lin, Y., Liu, X., Cai, X., Cao, J., Zhu, Q., Luo, X., Wan, X., Wu, H., Ye, J., Shan, C., Wu, Y., Cao, Y., Lin, Y., Yu, X., …, & Lin, H. (2026). Safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate for hyperkalemia management in China: actualize study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1744687
Vancouver
Shen N, Zeng X, Xie H, Zhang L, Yang J, Lin Y, et al. Safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate for hyperkalemia management in China: actualize study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1744687
BibTeX
@article{Shen2026,
author = {Shen, Nan and Zeng, Xin and Xie, Hua and Zhang, Lihong and Yang, Jing and Lin, Yongqiang and Liu, Xinyu and Cai, Xudong and Cao, Juan and Zhu, Qiang and Luo, Xun and Wan, Xin and Wu, Henglan and Ye, Jianming and Shan, Chunyan and Wu, Yifan and Cao, Yanping and Lin, Yang and Yu, Xiaoyong and Wang, Huimin and He, Jingdong and Tian, Shaojiang and Wu, Fenglei and Jiang, Xinxin and Li, Lu and Zuo, Li and Wang, Zhaohua and Xing, Changying and Yin, Xun and Zhao, Jianrong and Ma, Cong and Long, Gang and Li, Qing and Hu, Yao and Shi, Yifan and Lin, Hongli},
title = {Safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate for hyperkalemia management in China: actualize study},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1744687}
}
EUVIMED